Merck Snaps Six Straight Sessions of Losses
Summit Therapeutics Downgraded at Citi on Valuation
Merck & Co., Inc. (MRK): An Undervalued Wide Moat Stock to Buy According to Analysts
Express News | Merck: Will Continue Discussions With FDA to Help Enable Continued Access to Keytruda for Appropriate Patients
Express News | Merck Provides Update on Fda’s Oncologic Drugs Advisory Committee Meeting Discussion of Pd-L1 Expression Levels in Certain Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer Indications
Merck, Bristol-Myers Fail to Convince FDA AdCom on Wider Opdivo, Keytruda Use